Mechanisms of unexplained neurological deterioration after intravenous thrombolysis

Stroke

Volumn 45, Issue 12, 2014, Pages 3527-3534

  Tisserand, Marie ^a   Seners, Pierre ^a   Turc, Guillaume ^a   Legrand, Laurence ^a   Labeyrie, Marc Antoine ^a   Charron, Sylvain ^a   Méder, Jean François ^a   Mas, Jean Louis ^a   Oppenheim, Catherine ^a   Baron, Jean Claude ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Magnetic resonance imaging; Physiopathology; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN DAMAGE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN MAPPING; CEREBRAL REVASCULARIZATION; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DATA BASE; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; EARLY NEUROLOGICAL DETERIORATION; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; SINGLE BLIND PROCEDURE; STROKE PATIENT; VERY ELDERLY; VOXEL BASED MORPHOMETRY; BRAIN; COMPUTER ASSISTED DIAGNOSIS; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; BRAIN; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84922482179     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.006745     Document Type: Article

References (22)

1. Saver JL, Altman H. Relationship between neurologic deficit severity and final functional outcome shifts and strengthens during first hours after onset. Stroke. 2012;43:1537-1541.
2. Siegler JE, Martin-Schild S. Early neurological deterioration (END) after stroke: the END depends on the definition. Int J Stroke. 2011;6:211-212.
3. Seners P, Turc G, Oppenheim C, Baron JC. Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications [published online ahead of print June 26, 2014]. J Neurol Neurosurg Psychiatry. http://jnnp.bmj.com/content/early/2014/06/26/ jnnp-2014-308327.abstract. Accessed September 26, 2014.
4. Seners P, Turc G, Tisserand M, Legrand L, Labeyrie MA, Calvet D, et al. Unexplained early neurological deterioration after intravenous thrombolysis: incidence, predictors, and associated factors. Stroke. 2014;45:2004-2009.
5. Muir KW, Buchan A, von Kummer R, Rother J, Baron JC. Imaging of acute stroke. Lancet Neurol. 2006;5:755-768.
6. Alawneh JA, Moustafa RR, Baron JC. Hemodynamic factors and perfusion abnormalities in early neurological deterioration. Stroke. 2009;40:e443-e450.
7. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282.
8. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
9. Awadh M, MacDougall N, Santosh C, Teasdale E, Baird T, Muir KW. Early recurrent ischemic stroke complicating intravenous thrombolysis for stroke: incidence and association with atrial fibrillation. Stroke. 2010;41:1990-1995.
10. Georgiadis D, Engelter S, Tettenborn B, Hungerbühler H, Luethy R, Müller F, et al. Early recurrent ischemic stroke in stroke patients undergoing intravenous thrombolysis. Circulation. 2006;114:237-241.
11. Labeyrie MA, Turc G, Hess A, Hervo P, Mas JL, Meder JF, et al. Diffusion lesion reversal after thrombolysis: a MR correlate of early neurological improvement. Stroke. 2012;43:2986-2991.
12. Zaro-Weber O, Moeller-Hartmann W, Heiss WD, Sobesky J. Maps of time to maximum and time to peak for mismatch definition in clinical stroke studies validated with positron emission tomography. Stroke. 2010;41:2817-2821.
13. Takasawa M, Jones PS, Guadagno JV, Christensen S, Fryer TD, Harding S, et al. How reliable is perfusion MR in acute stroke? Validation and determination of the penumbra threshold against quantitative PET. Stroke. 2008;39:870-877.
14. Alawneh JA, Jones PS, Mikkelsen IK, Cho TH, Siemonsen S, Mouridsen K, et al. Infarction of 'non-core-non-penumbral' tissue after stroke: multivariate modelling of clinical impact. Brain. 2011;134(pt 6):1765-1776.
15. Tomsick T, Broderick J, Carrozella J, Khatri P, Hill M, Palesch Y, et al; Interventional Management of Stroke II Investigators. Revascularization results in the Interventional Management of Stroke II trial. AJNR Am J Neuroradiol. 2008;29:582-587.
16. Ludbrook J. Should we use one-sided or two-sided P values in tests of significance? Clin Exp Pharmacol Physiol. 2013;40:357-361.
17. del Zoppo GJ, Sharp FR, Heiss WD, Albers GW. Heterogeneity in the penumbra. J Cereb Blood Flow Metab. 2011;31:1836-1851.
18. Usnich T, Albach FN, Brunecker P, Fiebach JB, Nolte CH. Incidence of new diffusion-weighted imaging lesions outside the area of initial hypoperfusion within 1 week after acute ischemic stroke. Stroke. 2012;43:2654-2658.
19. Bang OY, Kim GM, Chung CS, Kim SJ, Kim KH, Jeon P, et al. Differential pathophysiological mechanisms of stroke evolution between new lesions and lesion growth: perfusion-weighted imaging study. Cerebrovasc Dis. 2010;29:328-335.
20. Molina CA. Reperfusion therapies for acute ischemic stroke: current pharmacological and mechanical approaches. Stroke. 2011;42(1 suppl):S16-S19.
21. Lansberg MG, Straka M, Kemp S, Mlynash M, Wechsler LR, Jovin TG, et al; DEFUSE 2 Study Investigators. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol. 2012;11:860-867.
22. Amaro S, Llull L, Urra X, Obach V, Cervera Á, Chamorro Á. Risks and benefits of early antithrombotic therapy after thrombolytic treatment in patients with acute stroke. PLoS One. 2013;8:e71132.